UTHealth Psychedelic Drug to Be Tested for Treatment-Resistant Depression in Houston
October 09, 2019
October 09, 2019
HOUSTON, Texas, Oct. 9 [TNSmedicalresearch] -- The University of Texas Health Science Center at Houston issued the following news release:
Psilocybin, a psychedelic drug believed to help rewire the brain, is now being studied to relieve treatment-resistant depression at The University of Texas Health Science Center at Houston (UTHealth) as part of a global Phase II clinical trial.
"It is a medication that can change or alter perceptions, cognition, thinking, and ho . . .
Psilocybin, a psychedelic drug believed to help rewire the brain, is now being studied to relieve treatment-resistant depression at The University of Texas Health Science Center at Houston (UTHealth) as part of a global Phase II clinical trial.
"It is a medication that can change or alter perceptions, cognition, thinking, and ho . . .